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REGULAR ARTICLE
The number of CD56dim NK cells in the graft has a major impact on risk of
disease relapse following allo-HSCT
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Charles Craddock,2 Jianmin Zuo,1,† Ram Malladi,1,2,† and Paul Moss1,2,†
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Key Points
• A stem cell graft NK cell
dose below 6.3 3 106
cells per kg associates
with risk of disease
relapse following
T-cell–depleted
allo-HSCT.
•Clinical outcomes of
patients undergoing
allo-HSCT may be im-
proved by setting an NK
cell threshold within
donor stem cell grafts.
The graft-versus-leukemia (GVL) effect of allogeneic hemopoietic stem cell transplantation
(allo-HSCT) is mediated by the donor immune system and acts to decrease the rate of disease
relapse. Although studies of posttransplant immune reconstitution have identiﬁed correlates
of clinical outcome, the number andproﬁle ofmature immune cells infusedwith the stemcell
graft is also likely to be an important determinant and has been relatively poorly studied.
We characterized immune cells within the stem cell graft of 107 patients who underwent
T-cell–depleted allo-HSCT and related this to clinical outcome. The number of natural killer
(NK) cells and T cells that were infused varied markedly between patients, but T-cell dose
was not an important factor in subsequent outcome. In contrast, the number of NK cells was
a powerful determinant of the risk of disease relapse. Patients who received an NK cell dose
below the median level of 6.3 3 106 cells per kg had a relapse rate of 40% at 2 years
posttransplant compared with only 6% for those whose stem cell graft contained a dose
above this value. Analysis of NK subsets showed that this effect was mediated primarily by
the CD56dim population of mature effector cells and that high-level expression of the
activatory protein DNAM on donor NK cells was also strongly protective. These observations
offer important insights into the mechanism of GVL and suggest that optimization studies of
the number of NK cells within the stem cell graft should be considered as a means to reduce
disease relapse.
Introduction
Allogeneic hemopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment of a
range of myeloid and lymphoid malignancies. Successful tumor elimination relies partially on a graft-
versus-leukemia (GVL) response that is mediated by the donor immune response and established within
the first few weeks following transplantation.1-3 Although many studies have related the clinical outcome
of transplantation to features of immune reconstitution4-7 or donor/host genotype,8,9 the potential
importance of the cellular composition within the initial stem cell infusion remains poorly defined. Indeed,
the number and diversity of immune cells within this product would be expected to influence immune
reconstitution and could play a significant role in determining patient outcome. Previous studies have
shown that a high CD341 cell dose in stem cell grafts obtained from peripheral blood is associated with
protection from relapse,10 and high CD81 T-cell doses correlate with improved survival.11 Natural killer
(NK) cell activity is controlled by a balance of inhibitory or activatory signaling,12 and there is considerable
heterogeneity between individual NK cell repertoires,13 which can predict susceptibility to viral infection.14
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Despite this, relatively little is known about the potential importance of
the nature of the NK cell infusion given at the time of transplant.
We determined the number and profile of immune cells within the
stem cell grafts of 107 patients who underwent allo-HSCT and
related this information to subsequent clinical outcome. We
demonstrate that the number of CD56dim NK cells infused at the
time of transplantation has a profound influence on the risk of
subsequent disease relapse, potentially through the expression of
the activatory receptor DNAM.
Methods
Patient cohort and sample collection
Samples were obtained from 107 consecutive patients undergo-
ing allo-HSCT for the treatment of hematological malignancies
between 2012 and 2015 at the Queen Elizabeth Hospital
Birmingham (ethics code: 051Q7071175) following written
consent and according to the Declaration of Helsinki. Donors
received a 5-day course of granulocyte colony-stimulating factor
prior to collection of their apheresis product. Peripheral blood
mononuclear cell samples were collected and processed within
24 hours following transplant of the final donor stem cell graft. The
number of total nucleated cells and CD341 cells in the donor stem
cell graft was determined by the National Health Service Blood
and Transplant Service.
Stem cell graft analysis
Analysis of the peripheral blood mononuclear cell component was
conducted using flow cytometric immunophenotyping. Live T and NK
cells were identified as part of the lymphocyte gate with exclusion of
cells expressing CD14 or CD19 (ECD; BeckmanCoulter) and use of a
viability dye (propidium iodide solution; Miltenyi). T cells were selected
as CD31CD562 whereas NK cells were selected as CD32CD561
(Biolegend; CD3 [HIT3a]; AF700, CD56 [HCD56]; APC-Cy7).
Receptor expression on NK cells was studied by use of monoclonal
antibodies against KIR proteins (Biolegend; CD158a/h [HP-MA4];
fluorescein isothiocyanate [FITC], CD158b [DX27]; FITC, CD158e
[DX9]; FITC), DNAM (Biolegend; DNAM/CD226 [11A8]; APC),
NKG2D (Biolegend; NKG2D/CD314 [1D11]; PerCP-Cy5.5), and
NKp46 (Biolegend; NKp46/CD335 [9-E2]; Pacific Blue). Cells were
washed inmagnetic-activated cell sorting buffer and surface stained on
ice, in the dark, for 30 minutes. Analysis was performed on a Gallios
flow cytometer (BeckmanCoulter) and interpretedwith Kaluza Analysis
Software 1.3 (Beckman Coulter).
Clinical outcome
A range of clinical outcomes were measured including relapse
incidence (RI), acute graft-versus-host disease (aGVHD), non-
relapse mortality (NRM), and overall survival (OS). RI was defined as
any event of relapse after the time of stem cell infusion, with death
from a nonrelapse cause acting as a competing risk. NRM was
defined as death from any cause other than disease relapse, with
death from relapse acting as the competing risk. Incidence of
aGVHD was determined by the diagnosis of grade 21 aGVHD by
100 days posttransplantation and assessed with a competing risk
of death before 100 days without aGVHD incidence.15 OS was
defined as death, from any cause, posttransplantation.16
Statistical analysis
Statistical analyses were performed using GraphPad Prism (7.0),
IBM SPSS Statistics (21), and R (the R project for statistical
computing 3.2.2). The effect of all baseline variables on OS was
estimated using the Kaplan-Meier method. Log-rank tests com-
pared survival curves. Cox proportional hazard regression analysis
was used to identify independent associations with OS.
The effect of all baseline variables on time to event outcomes with
competing risks (RI, aGVHD, and NRM) was estimated by cumulative
incidence analysis and tested using the Gray method.17 “Death by
any other cause” was the competing risk in each instance. The Fine
Table 1. Characteristics of patients within the study
Population characteristics Value Percentage
Total number in cohort 107
Patient age, median (range), y 56 (19-73)
Patients .60 y 44 41
Patient sex (male) 69 64
CMV at risk (2/1) 39 36
Disease
Myeloid (AML, CML, MDS, MF) 67 63
Lymphoid (ALL) 14 13
Non-Hodgkin lymphoma 19 18
Hodgkin lymphoma 7 7
Conditioning regimen
Full intensity
Cyclo/TBI 14 13
Reduced intensity
Flu/Melph 53 50
FLAMSA/Bu 14 13
Flu/Bu 12 11
BEAM 11 10
Flu/BEAM 3 3
T-cell depletion
Alemtuzumab 79 74
ATG 28 26
Donor characteristics
Donor age, median (range), y 48 (21-66)
Donor sex (male) 70 65
Female donor to male patient 22 21
Donor type
Matched sibling (10/10) 27 25
Matched unrelated donor (10/10) 70 65
Mismatched unrelated donor (9/10) 10 9
“CMV at risk (2/1)” indicates CMV seronegative patient receiving stem cell graft from a
CMV seropositive donor. Alemtuzumab dose: 50 mg (10 mg per day for 5 days). ATG dose:
FLAMSA/Bu, 1 mg/kg for 1 day, then 2 mg/kg for 2 days; Flu/Bu, 2.5 mg/kg for 2 days.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte
globulin; BEAM, BCNU etoposide Ara-C melphalan; Bu, busulfan; CML, chronic myeloid
leukemia; CMV, cytomegalovirus; Cyclo, cyclophosphamide; FLAMSA, fludarabine, Ara-C,
and amsacrine; Flu, fludarabine; MDS, myelodysplastic syndrome; Melph, melphalan; MF,
myelofibrosis; TBI, total body irradiation.
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and Gray regression method18 assessed the impact of independent
variables in a multivariate model.19,20 Baseline variables with a cutoff
point of P , .2 were included in multivariate analyses.
Results
Considerable heterogeneity is observed in the
composition of the lymphoid repertoire within the
stem cell graft
A total of 107 patients were recruited to the study, and all underwent
allo-HSCT as a treatment of a hematological malignancy (Table 1).
The median patient and donor ages were 56 years and 48 years,
respectively. A total of 70 patients (65%) underwent matched
unrelated donor transplant, with a further 10 patients (9%) undergoing
a single antigen mismatched transplant from an unrelated donor. Only
27 patients (25%) received transplants from matched sibling donors.
Of the entire cohort, 93 patients (87%) received reduced intensity
conditioning, whereas only 14 patients (13%) underwent myeloablative
conditioning. All patients received in vivo T-cell depletion with either
alemtuzumab (n 5 79, 74%) or ATG (n 5 28, 26%).
The donor apheresis bag was collected immediately after infusion
into the patient, and residual cells were collected for analysis.
Mononuclear cells were purified by density centrifugation, and flow
cytometry was used to identify subsets for subsequent correla-
tion with patient outcome. NK and T cells were identified by
CD561CD32 and CD562CD31 phenotype, respectively (Figure 1A),
from a “lymphocyte” gate in which nonviable cells, B cells, and
monocytes were removed. The number of lymphocytes, NK cells,
and T cells in this gate were calculated as a proportion of the
clinically measured absolute number of lymphocytes transferred in
the stem cell graft. This number was then corrected for the patient
weight in order to determine the “cell dose.”
The number of CD341 cells per kg in the graft was relatively
consistent across samples and ranged from 1.25 to 8.0 million cells
per kg (median 4.72; standard deviation [SD] 1.109), in keeping
with the target doses for infusion at our institution. In contrast,
significant differences were observed in both the number and
proportion of total lymphocytes, T cells, and NK cells between stem
cell grafts. In particular, the number of T cells varied from 0.04 to
458 million cells per kg (median 87.41; SD 84.07), whereas the
comparable range for NK cells was from 0.03 to 99 million cells per
kg with a median of 6.3 million cells per kg (SD 13.57) (Figure 1B).
Patients who receive high NK cell numbers in the
donor graft composition have a substantial reduction
in the rate of disease relapse
Given the considerable heterogeneity in the number of different
leukocytes infused within the stem cell graft, we next examined
whether these were related to subsequent clinical outcome. The
median doses of CD341 cells, lymphocytes, T cells, and NK cells
within the stem cell graft were 4.7, 186, 87, and 6.3 3 106/kg,
respectively. Patients were divided into 2 groups based on receipt of
a donor graft infusion with values above or below the median cell
dose for each of the 4 cell types. These groups were then assessed,
with a univariate analysis, against a range of clinical factors including
the incidence of disease relapse or aGVHD, NRM, andOS (Figure 2).
A striking positive association was apparent between the number of
NK cells infused and protection from disease relapse (P , .001)
(Figure 2A). Specifically, the relapse rate among patients who
received an infusion of NK cells above the median dose of
6.3 3 106/kg was only 6% at 2 years posttransplant compared with
40% in those who received an NK cell infusion below this value. As
such, infusion of the higher number of NK cells was associated with a
6.7-fold decrease in the rate of disease relapse. Receiver operating
characteristic curve analysis did not find an improved threshold than
the median NK cell dose to distinguish RI (supplemental Figure 1).
Patients who received an NK cell dose above the median level had
an OS at 2 years posttransplant days of 70% compared with 58%
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Figure 1. The number of T cells and NK cells delivered
within the stem cell product differs greatly between
patients. Plots showing flow gating strategy used to identify
lymphocytes, NK and T cells (A). Box and whisker graph
displaying dose range of T (range 0.04-458 3 106/kg;
median 87.4 3 106/kg), NK (range 0.03-99 3 106/kg; median
6.3 3 106/kg), and CD341 (range 1.25-8.0 3 106/kg; median
4.73 106/kg) cells in the stem cell product received by patients
in the cohort (B).
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for those in whom the graft composition was below the median.
This difference, however, did not reach statistical significance
(P 5 .161). No statistically significant differences were observed in
the risk of aGVHD or NRM in association with the NK cell dose in
the stem cell graft.
A statistically significant association was not observed between the
doses of infused CD341 cells, lymphocytes, or T cells and the
clinical outcomes of aGVHD, RI, NRM, or OS.
Multivariate analysis confirms that infusion of a stem
cell graft with an NK cell dose that is above the
median value is a determinant of the risk of relapse
In addition to NK cell dose within the stem cell graft, several
additional patient characteristics were found to be associated with
the risk of disease relapse at a statistical significance of ,.2 on
univariate analysis (supplemental Table 1). These included patient
age, donor type, type of T-cell depletion, patient hemopoietic stem
cell transplant comorbidity index (HCT-CI), and total lymphocyte
dose. The predictive power of NK cell dose was assessed within
multivariate models that included these parameters (Table 2).
Unrelated donor transplantation, low HCT-CI, nature of T-cell
depletion, and high NK cell dose all remained as independent
predictors of protection against disease relapse following multivar-
iate analysis. Importantly, the relative risk of relapse in patients who
received an NK cell infusion .6.3 3 106/kg compared with those
who received ,6.3 3 106/kg was 0.097, representing a 90%
reduction in relapse risk.
Several variables were associated with risk of developing aGVHD of
grade 2 or greater but only HLA mismatch and full-intensity
conditioning remained significant upon multivariate analysis. HLA
mismatch was also the only independent predictor of NRM. Finally,
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Figure 2. The number of NK cells in the stem cell product is protective against disease relapse. Relationship between the number of 4 different cell subsets administered
within the stem cell infusion and clinical outcome. The median number of CD341 cells, lymphocytes, T cells, and NK cells was defined, and transplants were divided into those
where the infusion contained a cell dose either above (blue) or below this median (red) value. Clinical outcome measures were RI (A), aGVHD (B), NRM (C), and OS (D). This
demonstrates that NK cell dose is the only parameter that influences disease relapse (P, .0001). Cumulative incidence analysis was tested using the Gray method. Log-rank tests
were used to analyze the Kaplan-Meier survival curves.
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the use of HLA mismatch between patient and donor, HCT-CI, type
of T-cell depletion, and NK dose were also found to be significant in
univariate analysis of predictors for OS, but only HLA mismatch and
HCT-CI remained as independent predictive risk factors following
multivariate analysis.
The number of CD56dim NK cells within the stem cell
graft is the predominant determinant of the risk of
disease relapse
In order to investigate the mechanisms underlying the association
between infusion of a high NK cell dose and relative protection from
disease relapse, we next went on to examine if a specific NK cell
subset was associated with this effect. The mean NK cell dose that
had been given in the stem cell graft in patients who went on to
suffer disease relapse was 4.93 106/kg compared with an average
of 11.5 3 106/kg in patients who did not relapse within 2 years
following allo-HSCT (Figure 3B). This was mirrored by the lower
average total NK cell number (0.39 3 109) and frequency of NK
cells (3.2% of all lymphocytes) received in the stem cell graft by
patients who relapsed compared with those who did not (0.913 109
and 5.7% of all lymphocytes, respectively).
The expression level of CD56 was distinguishable through flow
cytometry (Figure 1A) and was used to divide NK cells into immature
CD56bright and mature effector CD56dim NK cells (Figure 3A,C). We
therefore examined how the number of these 2 subsets within the stem
cell infusion was related to relapse risk. The risk of disease relapse was
not influenced by infusion of doses of CD56bright NK cells above or
below the median value. Importantly, however, the RI at 2 years
posttransplant for patients who received at least the median dose of
5.73 106/kg CD56dim NK cells was only 8.3% compared with 43% in
those who received a dose below this value (P, .0001). In relation to
average values, patients who went on to relapse had received
lower doses of both CD56bright (0.65 3 106/kg) and CD56dim cells
(4.33 106/kg) compared with those who did not relapse (1.23106/kg
and 10.4 3 106/kg, respectively). These observations indicate that
the number of mature cytotoxic effector CD56dim NK cells infused
within the stem cell graft is a powerful determinant of the strength of
the GVL effect following allogeneic transplantation.
Low expression of DNAM on CD56dim NK cells within
the stem cell graft is associated with an increased risk
of disease relapse
We next examined if features related to the phenotype of infused
CD56dim NK cells could further stratify the risk of disease relapse
within the patient cohort. Cell surface expression of the dominant
activatory receptors NKG2D, NKp46, and DNAM, and the inhibitory
KIR receptors CD158a/h, CD158b, and CD158e were examined
by flow cytometry (supplemental Figure 2). The expression of NKG2D
and NKp46 on CD56dim NK cells did not vary between patients who
relapsed compared with those who did not relapse. However, lower
expression levels of both the KIR proteins (P 5 .0159) and, even
more strikingly, the transmembrane activatory glycoprotein DNAM
(P 5 .0013) on CD56dim NK cells were associated with increased
risk of disease relapse (Figure 4). These data suggest that the
protective effect of high NK cell numbers within the stem cell graft
may be partially dependent on the DNAM1 CD56dim subset.
Discussion
Our findings demonstrate a strong association between the infusion of
high numbers of donor NK cells in the stem cell graft and relative
protection from disease relapse within the patient. This was
shown both in univariate and multivariate models. Mature effector
CD56dimDNAM1NK cells transferred within the graft were found to be
the phenotype most associated with this disease relapse protection.
These findings indicate that the number of NK cells infused at the
time of transplant is a strong determinant of the potency of the GVL
effect of allogeneic transplantation. NK cells have a half-life
of ;2 weeks and undergo active homeostatic proliferation,
following transfer into a T-cell–depleted host, to become
the dominant lymphocyte population at 1 month posttransplant
(supplemental Figure 3).21,22 Interestingly we found no correlation
between the dose of CD341 or NK cells in the stem cell graft and
number of NK cells in the peripheral blood at 1 month posttrans-
plant (supplemental Figure 4). However, only a minority of the total
lymphoid pool is present within peripheral blood, and as such, the
NK cell count does not necessarily reflect the total NK cell
population within patient tissue.23 Relatively modest differences in
Table 2. NK cell dose remains an independent predictor of RI in a
multivariate analysis
P Hazard ratio CI (2.5%) CI (97.5%)
RI
.56 years old .069 0.477 0.22 1.06
Alemtuzumab T-cell depletion .018 0.424 0.21 0.87
Sibling transplant <.001 4.588 1.99 10.60
High HCT-CI <.001 4.097 1.82 9.24
Lymphocyte dose . median .730 1.148 0.52 2.55
NK dose . median <.001 0.097 0.03 0.33
aGVHD
Female to male transplant .320 2.049 0.49 8.52
Mismatched unrelated donor (9/10) .030 7.988 1.23 51.96
Sibling transplant .720 0.649 0.06 7.02
Full-intensity conditioning .006 11.414 2.01 64.73
CD34 dose . median .130 0.341 0.08 1.39
Lymphocyte dose . median .860 1.176 0.19 7.21
T-cell dose . median .820 1.207 0.23 6.30
NRM
.56 years old .360 1.530 0.61 3.84
Mismatched unrelated donor (9/10) .014 2.970 1.24 7.10
OS
Mismatched unrelated donor (9/10) .012 3.449 1.32 9.02
Alemtuzumab T-cell depletion .127 0.560 0.27 1.18
High HCT-CI .008 2.525 1.27 5.03
NK dose . median .102 0.547 0.27 1.13
Patient characteristics or stem cell product cell dose with a univariate P , .2 association
with a clinical outcome were included in a multivariate model to assess independent
predictors in a regression model. (P, .2 in bold.) Fine and Gray regression method was used
for RI, aGVHD, and NRM to take competing risk into account. Cox proportional hazard
regression analysis was used to identify independent associations with OS.
CI, confidence interval.
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the initial “inoculum” of donor NK cells might translate into relatively
profound differences in tumor cell lysis within the first few weeks
following transplantation. It is noteworthy that the number of
invariant natural killer T cells within the graft has also been shown to
be associated with improved progression free survival.24
The mechanisms that might underlie this association are unclear at
the current time. The most straightforward explanation is that donor
NK cells have a direct lytic activity against residual tumor cells within
the patient.2,25 NK cells have potent activity against transformed cells,
and purified NK cell infusions have been shown to demonstrate
antitumor efficacy. However, an alternative possibility is that NK cells
might exert an indirect effect on the priming, expansion, or activity of
the alloreactive T-cell immune response that develops in the early
posttransplant period (Figure 5). As such, larger numbers of NK cells
might act to boost T-cell activation, perhaps through mechanisms
such as activation of host dendritic cells, or serve to suppress
inhibitory cell subsets.26,27 It should also be remembered that the
transplant conditioning regimen included T-cell depletion,28-30 and as
such, NK cells dominate the lymphoid repertoire during the early
phase of immune reconstitution; this may serve to accentuate the
clinical impact of the NK cell infusion at the time of transplant.31
NK cells demonstrate a range of cytotoxic and immunomodulatory
functions, and our data on the critical importance of the CD56dim
subset indicate that the cytotoxic activity of NK cells is a predominant
factor in providing protection against relapse. Further support is
provided by the observation that high-level expression of DNAM on
donor CD56dim NK cells and the overall dose of DNAM1CD56dim
NK cells within the stem cell graft are protective against disease
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Figure 3. CD56dim NK cells within the stem cell product are the major contributing factor to the association with disease relapse risk. Relationship between the
number of CD56bright and CD56dim NK cells administered within the stem cell infusion and RI. The median dose of both subsets was defined, and transplants were divided into those
where the infusion contained a cell dose either above (blue) or below this median (red) value (A). The cohort was then split into patients who relapsed or not within 2 years
posttransplant to assess absolute number (n 5 100), dose (n5 100), and percentage (n5 107) of all NK cells within the stem cell product (B). This was also shown in CD56bright
and CD56dim NK cells (n 5 100) (C). All NK groups proved to be significantly reduced in relapse patients.
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relapse (supplemental Figure 5). DNAM is a dominant activatory
molecule on NK cells and serves to trigger cytotoxic activity
against a range of targets. CD112 and CD155 are the 2 ligands
of DNAM and are expressed by AML blast cells.32 Moreover,
DNAM-dependent killing of AML cell lines has been shown in
vitro,33 and decreased expression of DNAM has been demon-
strated on NK cells taken from patients with AML and is believed
to act as a mechanism of tumor evasion.34 Interestingly, the
expression of DNAM was increased on CD56dim NK cells in CMV
seropositive donors (supplemental Figure 6) and may potentially
contribute toward the association between CMV reactivation
following allo-HSCT and protection from relapse.35,36 These
observations provide a potential mechanism for our findings as
“fresh” donor NK cells, which express high levels of DNAM,
would be expected to have the potential to directly lyse CD112-
or CD155-expressing tumor cells. Previous studies have used
donor NK cell infusions as a treatment of acute leukemia, and
Miller et al37 reported that 5 out of 19 patients with very high-risk
AML were able to obtain a complete response after infusion of
haploidentical NK grafts.
The magnitude of the impact of NK dose on risk of disease relapse
was striking, and our findings could have considerable impact for
clinical practice. Stem cell grafts that contain at least 6.33 106 NK
cells per kg are associated with 6.7-fold reduction in the risk of
relapse without increasing the risk of clinically significant aGVHD or
NRM. CD341 cell dose is already measured within stem cell
donations, and it would be relatively straightforward to also assess
the number of the CD32CD56dim cells. Where the NK dose is
inadequate, it is likely to be possible to add more cells from
processing of residual apheresis product. Alternatively, up to
2 3 107 NK cells per kg can be obtained following a single
donor lymphapheresis.37
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Figure 4. Patients receiving higher doses of DNAM1 CD56dim NK cells per kg within stem cell product demonstrate a reduced incidence of disease relapse. The
patient cohort was divided into patients who relapsed or remained in remission within 2 years posttransplant. Populations of CD56dim NK cells from the stem cell product
expressing NKG2D and NKp46 did not associate with relapse, but DNAM- and KIR-expressing cells did (n 5 71 for all phenotypic markers).
NK Cells Cytokine
CD112/CD155
DNAM
Tumour
Treg Cells
CD8+ T Cells 
APC
Figure 5. NK cells from the stem cell product may act in
either a direct or indirect manner to produce a GVL effect.
Residual tumor cells may potentially be eliminated via engage-
ment of DNAM on NK cells with ligands on the tumor cell. In
addition, NK cells may act indirectly to boost the alloreactive T-cell
response by influencing the immune environment through
cytokine release or modulation of host regulatory cell function.
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These findings indicate the profound influence that the initial NK cell
infusion has on determining the clinical features following allogeneic
stem cell transplantation. Further investigation of the mechanism
that underlies this association has the potential to uncover new
insights into NK cell biology and may have the potential to greatly
improve the clinical outcome of patients undergoing this procedure.
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